Predicting resistance by selection of signaling pathways

Translational Lung Cancer Research

Volumn 3, Issue 2, 2014, Pages 107-115

  Karachaliou, Niki ^a   Rosell, Rafael ^a,b,c   Molina, Miguel Angel ^a   Viteri, Santiago ^a  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Molecular Oncology Research (MORe) Foundation   (Spain)

Author keywords

Biomarkers; Epidermal growth factor receptor (EGFR) mutations; Lung cancer; Signaling pathways

Indexed keywords

AXL PROTEIN; BIM PROTEIN; CUB DOMAINCONTAINING PROTEIN 1; EPH2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; INTEGRIN B4; JANUS KINASE 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; SCATTER FACTOR; STAT PROTEIN; UNCLASSIFIED DRUG;

CANCER GROWTH; HUMAN; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; REMISSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84942512849     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2014.02.04     Document Type: Review

References (44)

1. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013;105:595-605.
2. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
4. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34.
5. Costa C, Molina MA, Drozdowskyj A, et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res 2014;20:2001-10.
6. Wannesson L, Viteri S, Costa C, et al. Signaling pathways modulating dependence of lung cancer on mutant epidermal growth factor receptor and mechanisms of intrinsic and acquired resistance to tyrosine kinase inhibitors. Curr Pharm Des 2013. [Epub ahead of print].
7. Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 2007;4:e294.
8. Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007;4:1669-79; discussion 1680.
9. Dasari VR, Velpula KK, Alapati K, et al. Cord blood stem cells inhibit epidermal growth factor receptor translocation to mitochondria in glioblastoma. PLoS One 2012;7:e31884.
10. Yu B, Liu W, Yu WM, et al. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies. Mol Cancer Ther 2013;12:1738-48.
11. Furcht CM, Muñoz Rojas AR, Nihalani D, et al. Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFRactivating mutations. Oncogene 2013;32:2346-55, 2355. e1-10.
12. Aceto N, Sausgruber N, Brinkhaus H, et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 2012;18:529-37.
13. Ivins Zito C, Kontaridis MI, Fornaro M, et al. SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis. J Cell Physiol 2004;199:227-36.
14. Wu CJ, O'Rourke DM, Feng GS, et al. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene 2001;20:6018-25.
15. Cragg MS, Kuroda J, Puthalakath H, et al. Gefitinibinduced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007;4:1681-89; discussion 1690.
16. Lazzara MJ, Lane K, Chan R, et al. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res 2010;70:3843-50.
17. Miura K, Wakayama Y, Tanino M, et al. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase. Oncogene 2013;32:5292-301.
18. Maroun CR, Naujokas MA, Holgado-Madruga M, et al. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 2000;20:8513-25.
19. Menis J, Giaj Levra M, Novello S. MET inhibition in lung cancer. Trans Lung Cancer Res 2013;2:23-9.
20. Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res 2013;19:2310-8.
21. Gusenbauer S, Vlaicu P, Ullrich A. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene 2013;32:3846-56.
22. Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010;16:3507-16.
23. Ye X, Li Y, Stawicki S, et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 2010;29:5254-64.
24. Faoro L, Singleton PA, Cervantes GM, et al. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem 2010;285:18575-85.
25. Noberini R, Koolpe M, Peddibhotla S, et al. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem 2008;283:29461-72.
26. Chang Q, Jorgensen C, Pawson T, et al. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 2008;99:1074-82.
27. Xu R, Yu Y, Zheng S, et al. Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood 2005;106:3142-9.
28. Dong S, Li FQ, Zhang Q, et al. Expression and clinical significance of SHP2 in gastric cancer. J Int Med Res 2012;40:2083-9.
29. Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013;382:720-31.
30. Dominguez CL, Floyd DH, Xiao A, et al. Diacylglycerol kinase a is a critical signaling node and novel therapeutic target in glioblastoma and other cancers. Cancer Discov 2013;3:782-97.
31. Rosell R, Karachaliou N. Lung cancer: maintenance therapy and precision medicine in NSCLC. Nat Rev Clin Oncol 2013;10:549-50.
32. Sordella R, Bell DW, Haber DA, et al. Gefitinibsensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 2004;305:1163-7.
33. Song L, Rawal B, Nemeth JA, et al. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 2011;10:481-94.
34. You M, Yu DH, Feng GS. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferonstimulated Jak/STAT pathway. Mol Cell Biol 1999;19:2416-24.
35. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
36. Csibi A, Fendt SM, Li C, et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013;153:840-54.
37. Howell JJ, Manning BD. mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab 2011;22:94-102.
38. Zheng L, Yang W, Wu F, et al. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res 2013;19:5372-80.
39. Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012;336:918-22.
40. Dando I, Donadelli M, Costanzo C, et al. Cannabinoids inhibit energetic metabolism and induce AMPKdependent autophagy in pancreatic cancer cells. Cell Death Dis 2013;4:e664.
41. Rocha GZ, Dias MM, Ropelle ER, et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 2011;17:3993-4005.
42. + cell proliferation in pancreatic cancer and have anticancer action. PLoS One 2013;8:e63969.
43. Würth R, Pattarozzi A, Gatti M, et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: a role for metformin-induced inhibition of Akt. Cell Cycle 2013;12:145-56.
44. Mizugaki H, Sakakibara-Konishi J, Kikuchi J, et al. CD133 expression: a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol 2013. [Epub ahead of print].